952023-06-2

Basic information

• Product Name: (S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate
• Synonyms: (S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate;[2-((S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethyl
• CAS NO: 952023-06-2
• Molecular Formula: C₁₂H₁₉N₃O₃
• Molecular Weight: 253.29756
• Mol File: 952023-06-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 463.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: 11.55±0.46(Predicted)
• CAS DataBase Reference: (S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate(952023-06-2)
• EPA Substance Registry System: (S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate(952023-06-2)

Safety Data

• Hazardous Substances Data: 952023-06-2(Hazardous Substances Data)

Usage

Description

(S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate is a carbamate derivative chemical compound with the structural formula C13H21N3O3. It features a tert-butyl group and is characterized by its unique molecular structure, which includes a 2-cyanopyrrolidinyl moiety and a 2-oxoethylcarbamate group. (S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate is of interest in the field of medicinal chemistry and drug development due to its potential to modify the properties of bioactive compounds and its utility in investigating structure-activity relationships in drug design.

Uses

Used in Pharmaceutical Industry:
(S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate is used as a building block for the synthesis of various drugs and biologically active molecules. Its unique structure and functional groups contribute to the development of new pharmaceutical agents with improved therapeutic properties.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, (S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate is employed as a valuable tool for investigating structure-activity relationships. Its incorporation into drug candidates can provide insights into how structural modifications affect the biological activity and pharmacokinetic properties of compounds.
Used in Drug Development:
(S)-tert-butyl 2-(2-cyanopyrrolidin-1-yl)-2-oxoethylcarbamate has potential applications in drug development, where it can be utilized to create novel drug candidates with enhanced efficacy, selectivity, and safety profiles. Its versatility in chemical synthesis allows for the exploration of various chemical modifications to optimize drug-like properties.

Upstream product

• 4530-20-5 BOC-glycine 
• 7531-52-4 L-prolinamide 
• 52293-28-4 (S)-tert-butyl 2-(2-carbamoylpyrrolidine-1-yl)-2-oxoethylcarbamate 
• 3392-07-2 tert-butyl N-{2-[(2,5-dioxopyrrolidin-1-yl)oxy]-2-oxoethyl}carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 952023-21-1 (2s,3aR,5S,6aS)-5-[2-((S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-octahydro-pentalen-2-yl phenyl-carbamate 
• 952137-52-9 (4R)-3-(2-((2s,3aR,6aS)-5-(4-fluorophenyl)-5-hydroxyoctahydropentalen-2-ylamino)acetyl)thiazolidine-4-carbonitrile 
• 1428264-81-6 (S)-1-(2-aminoacetyl)pyrrolidine-2-carbonitrile 4-methylbenzenesulfonate 
• 1145965-99-6 (S)-1-(2-(2-(3-(3,4-dimethylphenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile oxalate 
• 1145965-74-7 (S)-1-(2-(2-(3-(3,4-dimethylphenyl)-2-oxoimidazolidin-1-yl)ethylamino)acetyl)pyrrolidine-2-carbonitrile 

Relevant articles and documents

MARKING PRECURSOR WITH SQUARIC ACID COUPLING

The invention relates to a marking precursor incorporating a chelator or fluorination group for radiolabelling with 44Sc, 47Sc, 55Co, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 89Zr, 86Y, 90Y, 90Nb, 99mTc, 111ln, 135Sm, 140Pr, 159Gd, 149Tb, 160Tb, 161Tb, 165Er, 166Dy, 166Ho, 175Yb, 177Lu, 186Re, 188Re, 213Bi and 225Ac or with 18F, 131I or 211At, and one or two biological targeting vectors which are coupled to the chelator or fluorinating group via one or more squaric acid groups.

Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold

Fibroblast activation protein (FAP) is a serine protease that is generally accepted to play an important role in tumor growth and other diseases involving tissue remodeling. Currently there are no FAP inhibitors with reported selectivity toward both the closely related dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP). We present the discovery of a new class of FAP inhibitors with a N-(4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold. We have explored the effects of substituting the quinoline ring and varying the position of its sp2 hybridized nitrogen atom. The most promising inhibitors combined low nanomolar FAP inhibition and high selectivity indices (>10 3) with respect to both the DPPs and PREP. Preliminary experiments on a representative inhibitor demonstrate that plasma stability, kinetic solubility, and log D of this class of compounds can be expected to be satisfactory.

DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF

Disclosed are new dicycloazaalkane derivates represented by general formula (I), preparation processes and pharmaceutical compositions containing them, and the uses for treatment especially for dipeptidyl peptidase inhibitor (DPP-IV), in which each substitute group of general formula (I) is as defined in specification.